Ticagrelor Not Noninferior to Prasugrel in Diabetes Patients With Multivessel CAD After PCI

This randomized clinical trial was conducted across 66 clinical sites and enrolled 1,800 patients with both diabetes and multivessel coronary artery disease who were undergoing percutaneous coronary intervention (PCI). The study population specifically consisted of individuals with these two high-risk conditions, a group known to have elevated cardiovascular event rates. The trial aimed to compare two potent antiplatelet strategies in this contemporary setting.

The intervention was ticagrelor combined with low-dose aspirin, compared against prasugrel combined with low-dose aspirin. The specific dosing regimens for ticagrelor and prasugrel were not reported in the provided data. The treatment protocol was followed for 1 year, with patients monitored for clinical outcomes during this period. The comparator, prasugrel, served as the active control against which ticagrelor's performance was measured.

The primary outcome was a composite of death, nonfatal myocardial infarction, stroke, or major bleeding at 1 year. This occurred in 16.6% of patients (129 participants) in the ticagrelor group, compared to 14.2% of patients (107 participants) in the prasugrel group. This represented a risk difference of 2.33 percentage points, with a 95% confidence interval ranging from -2.07 to 6.74 percentage points (P = .12). Because the upper bound of the confidence interval exceeded the pre-specified noninferiority margin, ticagrelor failed to meet the threshold for noninferiority to prasugrel.

Key secondary outcomes showed similar patterns. The composite of death, myocardial infarction, and stroke occurred in 10.43% of patients with ticagrelor versus 8.63% with prasugrel (P = .30), a numerically higher rate that was not statistically significant. Major bleeding alone occurred in 8.41% of the ticagrelor group versus 7.14% of the prasugrel group (P = .19), again showing a numerical difference that did not reach statistical significance. Absolute numbers for these secondary outcomes were not reported.

Regarding safety and tolerability, the trial specifically reported on major bleeding events, which showed the numerical difference noted above. Detailed information on other adverse events, serious adverse events, rates of treatment discontinuation, and general tolerability profiles were not reported in the provided data. The absence of this comprehensive safety data limits a full assessment of the risk-benefit profile for each agent in this population.

These results should be interpreted in the context of prior landmark studies in antiplatelet therapy for ACS and PCI patients. Large trials like TRITON-TIMI 38 and PLATO established the efficacy of prasugrel and ticagrelor, respectively, against clopidogrel. However, direct head-to-head comparisons in specific high-risk subgroups like patients with both diabetes and multivessel disease have been limited. This trial adds to that comparative evidence, though it does not demonstrate superiority for either agent.

Key methodological limitations include the failure to meet the pre-specified noninferiority margin of 5%, which was the study's primary objective. The confidence interval crossing zero and the P-value of .12 indicate the observed difference could be due to chance. Other potential limitations not detailed in the provided data but common to such trials include possible selection bias, unmeasured confounding, and the generalizability of findings to clinical practice outside the trial setting. The lack of reported funding and conflict of interest information also limits assessment of potential biases.

For clinical practice, these findings suggest that in patients with diabetes and multivessel coronary artery disease undergoing PCI, prasugrel in combination with aspirin may be associated with a numerically lower rate of the composite ischemic and bleeding endpoint compared to ticagrelor, though this difference was not statistically significant. Given the failure to demonstrate noninferiority, clinicians might consider prasugrel as the preferred P2Y12 inhibitor in this specific, high-risk patient population when making evidence-based choices, pending further confirmatory data.

Several important questions remain unanswered. The trial did not establish whether the numerical trends favoring prasugrel represent a true clinical difference or random variation. Longer-term outcomes beyond 1 year are unknown. The optimal dosing strategy for these agents in this population was not explored. Furthermore, how these results apply to patients without diabetes, with different clinical presentations, or in combination with other contemporary therapies like potent statins or SGLT2 inhibitors requires further investigation. Finally, a more granular safety analysis including dyspnea with ticagrelor and specific bleeding types would provide a more complete picture for shared decision-making.